<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988869</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-22.12</org_study_id>
    <nct_id>NCT02988869</nct_id>
  </id_info>
  <brief_title>Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment</brief_title>
  <official_title>Comparison of Bronchodilator Efficacy of Tiotropium/Formoterol Combination Treatment Administered (qd) Via Discair® With Tiotropium (qd) Monotherapy or Tiotropium (qd) + Formoterol (Bid) Free Combination Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to asses the bronchodilator effect of once daily&#xD;
      Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.)&#xD;
      monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler +&#xD;
      formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable&#xD;
      moderate to severe COPD.&#xD;
&#xD;
      Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different&#xD;
      times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1&#xD;
      hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min&#xD;
      [10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective is to asses the bronchodilator effect of once daily&#xD;
      Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.)&#xD;
      monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler +&#xD;
      formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable&#xD;
      moderate to severe COPD.&#xD;
&#xD;
      Patients will be randomly assigned to receive Tiotropium/Formoterol combination as dry powder&#xD;
      for inhalation by Discair® (test inhaler, n = 29) or Tiotropium as dry powder capsule for&#xD;
      inhalation by HandiHaler or tiotropium dry powder capsule for inhalation by HandiHaler +&#xD;
      formoterol as dry powder capsule for inhalation by Aerolizer. Patients will be evaluated at 4&#xD;
      consecutive visits: baseline (enrollment), screening, treatment, and 24h after treatment.&#xD;
&#xD;
      For newly diagnosed and formerly diagnosed patients who are not on COPD medication, the&#xD;
      screening visit will be performed on the day of enrollment. For formerly diagnosed patients&#xD;
      receiving COPD treatment, the day of the screening visit will be based on the completion of a&#xD;
      run-in period, with the length determined by the specific medication. During the run-in&#xD;
      period, salbutamol (100 µg inhaler) will be prescribed as a rescue medication.&#xD;
&#xD;
      Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different&#xD;
      times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1&#xD;
      hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min&#xD;
      [10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean max change (ml) from baseline in FEV1 over a period of 24 h.</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean % change from baseline in FEV1 over a period of 24 h.</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean max change (ml) from baseline in FVC over a period of 24 h.</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean % change from baseline in FVC over a period of 24 h.</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 (AUC0-12) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 12 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC (AUC0-12) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 12 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 (AUC0-24) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC (AUC0-24) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 (AUC12-24) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC (AUC12-24) response</measure>
    <time_frame>From pre-treatment (10 minutes prior to the first dose of randomized study medication) to 24 hours post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to onset of bronchodilator effect</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to onset of maximum effect</measure>
    <time_frame>Pre-treatment (10 minutes prior to the first dose of randomized study medication) and post-treatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at 10 minutes prior to the first dose of randomized study medication and and post-treatment at 30. min, 60 min, 120 min, 180 min, 240 min, 360 min, 480 min, 600 min, 720 min, 840 min, 1440 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety (Physical examination, numbers of adverse reactions and abnormal laboratory values related to treatment)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium + Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Formoterol</intervention_name>
    <description>Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®</description>
    <arm_group_label>Tiotropium/Formoterol</arm_group_label>
    <other_name>TRITON 18/12 mcg Discair Inhalation Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>SPIRIVA 18 mcg Inhalation Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer</description>
    <arm_group_label>Tiotropium + Formoterol</arm_group_label>
    <other_name>FORADIL 12 mcg Inhalation Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler</description>
    <arm_group_label>Tiotropium + Formoterol</arm_group_label>
    <other_name>SPIRIVA Inhalation Powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥40 years with COPD diagnosis according to the current GOLD (The Global&#xD;
             Initiative for Chronic Obstructive Lung Disease) strategy.&#xD;
&#xD;
          -  Patients who have symptomatic stable moderate to severe COPD diagnosis with&#xD;
             post-bronchodilator FEV1/FVC ratio &lt;0.70, and FEV1 &lt;80% of predicted normal at&#xD;
             screening visit.&#xD;
&#xD;
          -  Current smokers or ex-smokers with a smoking history of at least 10 pack-years&#xD;
&#xD;
          -  Patients who have no exacerbation within last 4 weeks&#xD;
&#xD;
          -  Female patients with childbearing potential using effective birth control method&#xD;
&#xD;
          -  Patients who signed written informed consent prior to participation&#xD;
&#xD;
          -  Patients who accept to comply with the requirements of the protocol&#xD;
&#xD;
          -  Patients who have a capability of communicate with investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to drugs contains anticholinergics, beta-adrenergic,&#xD;
             lactose&#xD;
&#xD;
          -  Diagnosis of asthma&#xD;
&#xD;
          -  Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening&#xD;
             visit or during run-in period.&#xD;
&#xD;
          -  Patients who had COPD exacerbation or lower respiratory track infections that required&#xD;
             antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to&#xD;
             screening visit or during run-in period.&#xD;
&#xD;
          -  Patients who have a history of myocardial infarction, hearth failure, acute ischemic&#xD;
             coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks&#xD;
&#xD;
          -  Patients who have lung cancer&#xD;
&#xD;
          -  Patients with active tuberculosis&#xD;
&#xD;
          -  Patients who use oxygen therapy&#xD;
&#xD;
          -  Patients who have common interstitial lung diseases like cystic fibrosis,&#xD;
             bronchiolitis obliterans&#xD;
&#xD;
          -  Patients with serious liver or renal disease that leads to organ failure&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  History of allergic rhinitis and atopy&#xD;
&#xD;
          -  Known symptomatic prostatic hypertrophy requiring drug therapy or operation&#xD;
&#xD;
          -  Patients with narrow-angle glaucoma requiring drug therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinar Yildiz, Professor Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital-Turkey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019 Dec;35(12):2187-2196. doi: 10.1080/03007995.2019.1654722. Epub 2019 Sep 16.</citation>
    <PMID>31397184</PMID>
  </results_reference>
  <results_reference>
    <citation>Yildiz BP, Bayraktaroglu M, Gunen H. Reply: Re: Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 μg once daily via a discair inhaler), tiotropium alone (18 μg by handihaler) or combined with formoterol (12 μg twice daily by aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019;35(12):2187-2196. Curr Med Res Opin. 2020 Jun;36(6):1061-1062. doi: 10.1080/03007995.2020.1754187. Epub 2020 Apr 29.</citation>
    <PMID>32270722</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Tiotropium</keyword>
  <keyword>Formoterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

